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Abstract
Raised awareness in the mutation genes known as, BRCA1 and 
BRCA2, has dramatically increased the number of women undergoing 
genetic testing to inform them if they are at risk of developing breast 
cancer. This paper explores the main influences that can affect the 
woman’s decision making processes when tested positive as BRCA1 or 
BRCA2 mutation carriers. The paper concludes that there is a need for 
a more informed and person-centred approach to genetic counselling 
for women post-test.
Introduction
By 1995 it became apparent that breast cancer susceptibility genes, 
BRCA1 and BRCA2, were implicated in hereditary breast and ovarian 
cancers [1,2]. The presence of a BRCA mutation has been shown to 
significantly increase a woman’s chances of getting breast or ovarian 
cancer in the future. The lifetime risk of breast cancer is as high as 70% 
for BRCA1 mutation carriers, and 55% for BRCA2 mutation carriers, 
while the ovarian cancer risk is as high as 40% for BRCA1 mutation 
carriers, and 20% for BRCA2 mutation carriers [3]. To put this into 
perspective, breast cancer is the most common cancer in females in 
the United Kingdom (UK), accounting for almost 31% of all female 
cases, while ovarian cancer is the sixth most common cancer in the 
UK, accounting for almost 4% of all female cases [4]. In what has been 
described in the media as the ‘Angelina Jolie effect’, there has been a 
marked increase in the number of women seeking referrals for genetic 
testing due to raised awareness of BRCA mutations [5]. 
A positive BRCA mutation carrier result can be psychologically 
overwhelming, and have a profound effect on the quality of life of the 
woman as they go through the decision-making process of managing 
their risk either by surveillance or surgery [6,7]. The delivery of genetic 
counselling is extremely important for women and their families at this 
time and this role is normally undertaken by advanced practice nurses 
pre and post-test. Genetic counsellors provide valuable support for 
those undergoing genetic testing for gene mutations, and help guide 
individuals through challenging and complex decision making to 
enable them to manage their risk based on clinical guidelines 164 [8]. 
The continued prevalence of breast and ovarian cancers coupled 
with increased awareness and demand for genetic testing and 
counselling, highlights the need for a strong evidence base for 
advanced nurse practitioners to ensure they continue to deliver current 
and effective care [4,5]. This paper discusses four key issues of 
proximity, social support, control and survivorship that surround the 
provision and delivery of genetic counselling post-test for women with 
a BRCA mutation.
Proximity
Women with a first degree relative that had been affected by breast 
or ovarian cancer tend to use a ‘proximity filter’ to assess their own 
perceived risk and determine the risk-management strategy of surgery 
or surveillance [9]. “One way that I think my mom’s death directly 
impacted me was that for a long time….I assumed I would get cancer 
and die early” [10].
Jeffers et al. [11] suggested that those individuals with a BRCA 
mutation consider risk to be experiential rather than quantified. 
Furthermore, Litton et al. [12] reported that 84% of participants with 
a previous family history of breast or ovarian cancer felt that a risk 
reducing mastectomy was the most effective way of reducing their 
fear of getting cancer. This was evaluated to be a result of proximity 
to cancer which might begin years before they are tested for the BRCA 
mutation [9]. Hoskins et al. [10], claims that it becomes apparent that 
the loss of a mother or close relative connects the BRCA mutation 
carrierl with proximity to cancer. This is highlighted further by the 
reports that women who chose surveillance, did not have the same 
“lived” experience of a mother, sister or brother who died from cancer. 
As a result of no experiential proximity to cancer they continued with 
surveillance and ‘perceived’ cancer to be further away [9]. These 
differences in perception created by proximity require consideration 
during post-test counselling to ensure that a truly person centred 
delivery of care can be designed around the individual.
“I have…no idea what cancer looks like. I have no idea what cancer 
feels like….I’ve just got this big fat number the geneticist flopped in 
front of me when she gave me my status that says eighty-seven percent…
.I have no sense how else to gauge it” [10]. 
Howard et al. [13] further contributes to this discussion through 
the self-schema theory which are mental representations of the self that 
can change over time based on a women’s perception of risk. The self-
schema theory is applicable to the proximity theme when considering 
how individuals perceive risk over time. 
“I’m definitely getting a little bit stressed and tired of all the testing 
and wondering how much longer I want to do this…I’m considering 
doing it at a younger age and not necessarily having to breast-feed my 
children” [10].
Social Support
Social support and the need for follow-up sessions with genetic 
counselling is recognised as important so that women feel more 
supported.
“you give me this information and nobody has done anything about 
it…It’s like somebody has given you a death sentence…I just don’t think 
it’s right to give people, tell people that and then there is nothing to 
back it up” [11].
From a different perspective it was found that partners of young 
BRCA1 and BRCA2 mutation carrier women are sometimes very 
involved in decision-making and planning for risk management. This 
type of social support seems to have a positive effect on younger women 
which is important as evidence suggests that they can feel like they are 
under a ‘black cloud’ [10]. 
“He came to the decision before I did…he sits me down and says, 
we need to have a talk. I think the plan needs to change” [10].
Unfortunately not all BRCA mutation carriers felt they were 
supported in their decision making which could lead to avoidance of 
contact with unsupportive individuals, thus creating an element of 
social isolation. “But she [the family member] actually thought that risk 
reducing mastectomy was a stupid decision, and I had a few reactions 
like that” [10].
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Survivorship
This final issue considers the element of survivorship throughout 
the decision making process. Howard et al. [13], claimed that the 
self-schemas theory promotes survivorship in four contexts including 
protecting one-self from cancer, identity, emotional well-being and 
relationships. On balance, women weigh the potential benefits and 
consequences of management options to ‘protect themselves from 
cancer’. “I definitely weigh pros and cons……..the risks of the surgery 
were minor compared to the risks involved with cancer” [13]. In terms 
of identity and emotional well-being, women consider the impact of 
choosing invasive surgery to manage their risk. When considering 
relationships affecting decision-making, women consider how 
survivorship is important to their role and responsibilities as mothers, 
wives, partners, sisters, and daughters [18]. The paramountcy principle 
was an overriding factor for choosing the surgical route in the literature 
as women balanced their individual needs against the needs of present 
or future children and their role as a wife and mother. 
“I’ll be driving on the road…and I literally have daydreams that I 
have two kids. I’m gone. I have two kids and… I’m not there…I want to 
make sure I’m around…Whatever that takes” [10].
Conclusion
This paper has explored the effectiveness of genetic counselling in 
women who are BRCA mutation carriers. There is a sense that the current 
medical model in use is dominated by statistics and needs adapted to 
take into consideration qualitative evidence that explores the woman’s 
quality of life post genetic testing. Although statistics are an important 
element of informed risk assessment, the qualitative evidence would 
suggest that women who are BRCA mutation carriers may base some 
of their risk-assessment on a ‘nexus of decision-making,’ and thus filter 
perception of risk via experiential rather than quantified outcomes [11]. 
By providing a more balanced view in terms of statistical probabilities 
and quality of life, the woman’s decision making process should be a 
more improved and informed approach.
The key issues discussed in this paper that of proximity, control, 
social support and survivorship need to be explored through genetic 
counselling with a patient-centred approach as well as a familial 
approach to improve quality of life. Proximity to cancer and experience 
of a close relative with cancer were vital aspects that influenced decision-
making across the spectrum. Women were more empowered by their 
decision-making when they were in control compared to those who 
attributed disempowerment to a lack of control. Furthermore, Social 
support became more prevalent when there was no familial experiential 
proximity to cancer. Survivorship identified on-going long-term support 
needs such as body image, identity, emotional well-being and effect on 
relationships. Survivorship issues span long beyond the scope of this 
discussion but include support needs related to having children in the 
future either via IVF or other means, coping with a new body image 
and the effect that has on their relationships whether married or single. 
These four key issues of proximity, social support, control and 
survivorship should be considered as an integral part of all genetic 
counselling in order to minimise the psychosocial impact and improve 
the quality of life for women who are BRCA mutation carriers. Neutral 
genetic counselling without prejudice is crucial for a woman to take 
ownership of her risk promoting empowerment as opposed to the ‘one-
size-fits-all’ approach that tends to be based on statistical significance 
rather than patient centred outcomes.
Further qualitative exploration in this area is necessary in order to 
inform clinical practice and provide women who are BRCA mutation 
carriers with the person centred care they require post genetic testing. 
The key issues discussed in this paper could be used as a means to shape 
future research and systematic review into this expanding area of health 
care.
Control
Control is pivotal to women during this genetic counselling time 
and whether the woman felt empowered or disempowered will have 
an effect on their post-operative recovery following any surgery. 
Supporting evidence from Hesse-Biber [9], identifies a distinction 
between “following and “choosing,” and suggests that it parallels 
the concepts of disempowerment and empowerment. When viewed 
from this angle it becomes apparent that it is important for health care 
professionals such as nurses to treat the person and not just the cause 
to promote a person centred approach thus promoting empowerment 
and a sense of control with decision-making. “I’m going to get cancer 
if I don’t do something about it…I wanted to do something, to take 
control…I didn’t want to be a cancer patient, I’m just going to have 
the surgery” [9].
In terms of accountability, the use of evidence based practice is 
an essential element towards the UK National Health Service (NHS) 
operating in a cost-effective manner [14]. However, it is also important 
that professional standards and quality of care are not compromised as 
a result of the diminishing healthcare budget [15]. The clinical care 
guidelines (CG164) produced by the National Institute for Health and 
Care Excellence (NICE) [8], provide evidence based support for both 
practitioners and women affected by the BRCA mutation or those with 
a family history of breast cancer.
Although care delivery cannot always involve empowerment in a 
cancer diagnosis, it is achievable to promote a sense of control through 
empowerment via preventative treatment measures by adopting 
an integrated, informed and person-centred approach to genetic 
counselling [14]. The challenge faced with the effectiveness of genetic 
counselling is that the evidence is dominated by a medical healthcare 
model, were making sense of the BRCA mutation using statistics is 
the standard [9]. Contrary to this statistical approach this review has 
reported a ‘nexus of decision-making’ whereby women that are BRCA 
mutation carriers filter ‘perceived’ cancer risk according to experience 
and proximity to cancer rather than statistics. This more experiential 
approach taken by women therefore questions the current style of 
genetic counselling were statistics and probability equations could be 
potentially ineffective to assist decision-making for women with the 
BRCA mutation. 
It could be suggested that this is further corroborated by supporting 
evidence that a significant number of women are seeking social 
support online due to perceived deficiencies in genetic counselling 
[13]. Although it could be assumed that in todays ‘e’ modality women 
will naturally review the available material on the internet to help 
in the decision making process. Indeed a study by Wang et al. [16] 
indicated that breast cancer is one of the most popular medical search 
queries on the internet in America. “I did go on the internet and read, 
get some literature and books, talk to the doctors…I think I made the 
right decision and I think I based that decision on what I think I know.” 
[13]. It is extremely important that genetic counsellors are aware of the 
websites most frequented by women, so that they have the evidence to 
guide and support women through the many hurdles and sometimes 
conflicting evidence available online.
Haffty and Lannin [17] promote risk reducing mastectomy in 
women with a family history. However, the evidence recommends 
a cautious and neutral approach to guidance where the woman has 
less social support in her personal life and is relying on health care 
professionals to empower her by guiding her through the decision-
making process based on the CG164 recommendations [8]. This is 
crucial to avoid women having feelings of regret and disempowerment 
on their decision-making post-surgery. “You have to have a 
mastectomy…I had no information. I went in blind, and I had no one to 
talk to…I had my doctors and their nurses, and everybody was great, 
but that’s all…. (if I choose surveillance)…I guess I die…And that one 
sentence did it for me” [9].
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